Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (281-290 of 308) with videos related to

Pageof 31
Sort By:
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS studyPaul Verboom, Harm van Tinteren, Otto S Hoekstra, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validityPeter Tugwell, Maarten Boers, Maria-Antonietta D'Agostino, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for patient-reported outcomesJohn R Kirwan, Susan J Bartlett, Dorcas E Beaton, et al.
Seminars in Arthritis and Rheumatism|August 4, 2014
A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Mickaël Hiligsmann, Cyrus Cooper, Francis Guillemin, et al.
Annals of the Rheumatic Diseases|January 23, 2021
EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)Félicie Costantino, Loreto Carmona, Maarten Boers, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: discrimination and feasibilityGeorge Wells, Dorcas E Beaton, Peter Tugwell, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
The Lancet. Rheumatology|August 16, 2021
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studiesLaura Boekel, Maurice Steenhuis, Femke Hooijberg, et al.
Pageof 31

Showing results (281-290 of 308) with videos related to

Sort By:
Pageof 31
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS studyPaul Verboom, Harm van Tinteren, Otto S Hoekstra, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validityPeter Tugwell, Maarten Boers, Maria-Antonietta D'Agostino, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for patient-reported outcomesJohn R Kirwan, Susan J Bartlett, Dorcas E Beaton, et al.
Seminars in Arthritis and Rheumatism|August 4, 2014
A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Mickaël Hiligsmann, Cyrus Cooper, Francis Guillemin, et al.
Annals of the Rheumatic Diseases|January 23, 2021
EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)Félicie Costantino, Loreto Carmona, Maarten Boers, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: discrimination and feasibilityGeorge Wells, Dorcas E Beaton, Peter Tugwell, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
The Lancet. Rheumatology|August 16, 2021
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studiesLaura Boekel, Maurice Steenhuis, Femke Hooijberg, et al.
Pageof 31